Biotech Industry's "Biopharming" Prospects Fizzle
Opposition to the controversial practice of genetically engineering crops to produce pharmaceutical and industrial compounds, also called "biopharming", has been building steadily since 2002, according to a risk profile released today by Friends of the Earth (FoE) and the U.S. Public Interest Research Group (U.S. PIRG).
In the latest setback, San Diego-based Epicyte Pharmaceutical, a leading developer of pharmaceutical corn, announced on May 6th it would close its doors. Another blow came in early April, when the U.S. Department of Agriculture (USDA) denied Sacramento-based Ventria Bioscience a permit to grow 120 acres of pharmaceutical rice in Southern California, a decision applauded by Friends of the Earth and U.S. PIRG.
Opposition to the controversial practice of genetically engineering crops to produce pharmaceutical and industrial compounds, also called "biopharming", has been building steadily since 2002, according to a risk profile released today by Friends of the Earth (FoE) and the U.S. Public Interest Research Group (U.S. PIRG).
In the latest setback, San Diego-based Epicyte Pharmaceutical, a leading developer of pharmaceutical corn, announced on May 6th it would close its doors. Another blow came in early April, when the U.S. Department of Agriculture (USDA) denied Sacramento-based Ventria Bioscience a permit to grow 120 acres of pharmaceutical rice in Southern California, a decision applauded by Friends of the Earth and U.S. PIRG.
0 Comentarios:
Publicar un comentario
Suscribirse a Comentarios de la entrada [Atom]
<< Página Principal